Stock Research: Charles River Laboratories

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Charles River Laboratories

NYSE:CRL US1598641074
22
  • Value
    24
  • Growth
    37
  • Safety
    Safety
    71
  • Combined
    29
  • Sentiment
    25
  • 360° View
    360° View
    22
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Charles River Laboratories International, Inc. is a drug development company that provides essential products and services globally to accelerate research and drug development. Its main businesses include Research Models and Services (Research Models, Research Model Services, Cell Solutions), Discovery and Safety Assessment (regulated and non-regulated DSA services, therapeutic discovery and optimization, in vitro and in vivo studies, laboratory support, consulting), and Manufacturing Solutions (Microbial Solutions, Biologics Solutions). It operates around the globe. In the last fiscal year, the company had 18600 employees, a market cap of $7584 million, profits of $1408 million, and revenue of $4050 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 22 (better than 22% compared with alternatives), overall professional sentiment and financial characteristics for the stock Charles River Laboratories are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Charles River Laboratories. Only the consolidated Value Rank has an attractive rank of 71, which means that the share price of Charles River Laboratories is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 71% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 37, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 24, meaning the company has a riskier financing structure than 76% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 75% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 25. ...read more

more
Index
Employee Health US
S&P MIDCAP
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 9-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
71 63 51 37
Growth
37 29 31 55
Safety
Safety
24 42 20 12
Sentiment
25 19 86 43
360° View
360° View
22 12 34 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
25 3 70 57
Opinions Change
75 13 36 60
Pro Holdings
n/a 74 88 21
Market Pulse
30 26 67 58
Sentiment
25 19 86 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
71 63 51 37
Growth
37 29 31 55
Safety Safety
24 42 20 12
Combined
29 23 12 12
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
73 73 68 45
Price vs. Earnings (P/E)
63 63 57 67
Price vs. Book (P/B)
67 53 40 22
Dividend Yield
1 1 1 1
Value
71 63 51 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
18 42 23 42
Profit Growth
30 22 48 57
Capital Growth
56 63 25 30
Stock Returns
57 25 61 81
Growth
37 29 31 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
32 28 20 22
Refinancing
29 31 9 17
Liquidity
48 55 71 56
Safety Safety
24 42 20 12

Similar Stocks

Discover high‑ranked alternatives to Charles River Laboratories and broaden your portfolio horizons.

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.